Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: A GTE study

#3132

Introduction: Although 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA) is a key biomarker in midgut NET, it may be inaccurate and inconvenient.

Aim(s): We compared the diagnostic performances of 24u5HIAA, overnight urinary 5HIAA (Ou5HIAA) and plasmatic 5HIAA (p5HIAA) in midgut NET.

Materials and methods: This prospective multicenter study included 80 patients with metastatic midgut NET and 17 control patients with irritable bowel syndrome. 24u5HIAA, Ou5HIAA and p5HIAA were measured in urine and plasma collected on two consecutive days following specific diet. Biomarker reproducibility was evaluated by the Spearman test. Diagnostic performance was assessed by the area under receiver-operator curve (AUROC). Correlations with the main clinical features and declared observance to the diet were assessed using AUROC and logistic regression models.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: de Mestier L

Authors: de Mestier L, Savagner F, Brixi H, Do Cao C, Dominguez S,

Keywords: neuroendocrine tumor, carcinoid syndrome, 5-hydroxyindolacetic acid, biomarker, diagnosis,